Syndax Pharmaceuticals (SNDX) Long-Term Deferred Tax (2022 - 2023)
Syndax Pharmaceuticals (SNDX) recorded quarterly Long-Term Deferred Tax of $79.6 million in Q4 2023, up 62.78% quarter-over-quarter from $48.9 million in Q4 2022, and up 62.78% on a YoY basis from $48.9 million in Q4 2022.
Syndax Pharmaceuticals (SNDX) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
Syndax Pharmaceuticals' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $79.6 million for Q4 2023.
- In Q4 2023, Long-Term Deferred Tax rose 62.78% year-over-year to $79.6 million; the TTM figure through Dec 2023 stood at $79.6 million (up 62.78% YoY), while the FY2023 annual figure was $79.6 million, up 62.78% from the prior year.
- Long-Term Deferred Tax was $79.6 million for Q4 2023 at Syndax Pharmaceuticals, up from $48.9 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $79.6 million in Q4 2023 to a low of $48.9 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Syndax Pharmaceuticals | 1.69 Bn | 1.34 Bn | 53.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 79.60 Mn |
| Dec 31, 2022 | 48.90 Mn |